Tirzepatide vs Retatrutide — Dual vs Triple Agonist Comparison
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist available via prescription for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) being studied in clinical trials by Eli Lilly — it is not FDA-approved and is not legally available outside a clinical trial setting. The two represent different stages of the same pharmacological development pathway.
Mechanism Comparison
| Property | Tirzepatide (Mounjaro / Zepbound) | Retatrutide (LY3437943) |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + Glucagon (triple agonist) |
| Development phase | FDA-approved (two indications) | Phase 2/3 clinical trials |
| Brand names | Mounjaro (T2DM), Zepbound (weight management) | None — investigational only |
| Manufacturer | Eli Lilly | Eli Lilly (LY3437943) |
| Legal availability | Prescription only (US) | Clinical trial access only |
| Key distinction | Currently prescribed; large trial dataset exists | More receptors targeted; earlier evidence stage |
Evidence Maturity
| Dimension | Tirzepatide (Mounjaro / Zepbound) | Retatrutide (LY3437943) |
|---|---|---|
| Clinical trial evidence | SURPASS and SURMOUNT programs — large, published Phase 3 trials | Phase 2 TRIUMPH-1 published; Phase 3 ongoing (TRIUMPH-2/3) |
| Published data depth | Extensive — multiple peer-reviewed publications | Growing — early results show greater weight loss magnitude |
| Post-market data | Available (FDA adverse event reports, real-world studies) | Not yet available |
Regulatory Status
Tirzepatide is FDA-approved for type 2 diabetes and chronic weight management. The FDA has issued warnings about compounded semaglutide and tirzepatide — compounded versions are not FDA-approved and carry additional risk. Retatrutide is investigational and not available outside clinical trials. Research-vendor products claiming to be retatrutide are unverified and may be counterfeit.
Quality and COA Checklist
- Third-party COA: Both compounds should have batch-linked certificates from independent laboratories
- Purity ≥98%: HPLC/MS data should be visible — not just a stated percentage
- Research-use-only labeling: Vendors should not provide dosing, injection, or human-use guidance
- Transparent payment: Legitimate vendors have clear business payment methods and refund policies
- Source dating: COAs should be within the last 6–12 months for current inventory
Frequently Asked Questions
Is retatrutide available to prescribe?
No. Retatrutide (LY3437943) is still in clinical trials and has not received FDA approval. It is not legally available to patients outside a registered clinical trial. Any vendor claiming to sell retatrutide is offering an unverified research chemical.
What makes retatrutide different from tirzepatide?
Retatrutide adds a third receptor target — the glucagon receptor — to the dual GIP/GLP-1 mechanism of tirzepatide. Early trial data suggests this may produce greater weight loss, but the safety profile is less established than tirzepatide's large Phase 3 dataset.
Can I buy retatrutide from research vendors?
Products claiming to be retatrutide from research vendors cannot be verified as genuine. Retatrutide is a proprietary investigational compound — there is no approved reference standard available to independent testing labs. Extreme caution is warranted.
Has tirzepatide been FDA-approved?
Yes. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. It is available by prescription only.
Where can I find trial information on retatrutide?
ClinicalTrials.gov lists retatrutide trials under Eli Lilly (LY3437943). The TRIUMPH-1 program published Phase 2 results, and Phase 3 trials are ongoing.
Related Pages
Peptide Vendor Rankings → · How to Read a COA → · Our Evaluation Methodology →
Verification Notes for Tirzepatide vs Retatrutide — Dual vs Triple Agonist Comparison
This file is reviewed as part of the The Peptide Reviewer documentation system, which means the page is not judged by headline confidence alone. The desk checks whether the claim has a date, whether the source can be opened by a reader, whether commercial language is separated from editorial scoring, and whether a medical or regulatory boundary is visible before the reader reaches any vendor context.
For tirzepatide vs retatrutide, the practical standard is source literacy. A reader should be able to trace the page back to primary records, compare those records with the current vendor or compound claim, and see what the page does not prove. If a vendor changes a COA, removes a lab report, edits a product page, or adds health-outcome language after this review date, the conclusion can change. That is why this publication keeps source dates, correction rules, and reviewer scope close to the article body instead of hiding them in a footer.
The editorial team uses the same baseline checks across peptide vendor reviews, compound explainers, comparison pages, trust pages, and author pages. First, the page must identify the entity or topic clearly. Second, it must point readers toward primary-source verification. Third, it must avoid personal-use instructions and medical recommendations. Fourth, it must disclose when affiliate economics could exist and state that payment does not change scoring, inclusion, risk labels, or rank order.
When the page discusses a compound, the review separates published research context from research-market product claims. Published studies, trial records, or regulatory documents can describe a molecule, but they do not verify a private vendor batch. When the page discusses a vendor, the review separates a vendor's public marketing from documentation that can be checked, including batch-linked certificates, lab identity, source dates, claims language, and correction history.
Readers should treat this file as an audit trail, not a shortcut. The safest way to use it is to open the listed sources, confirm the current date on the vendor or regulatory record, and compare that source with the page summary. If the source and summary disagree, the source wins until the page is corrected. If the source cannot be found, the claim should be treated as unverified.
This added review note also gives crawlers and readers the same context that the editors use internally: what kind of evidence matters, which trust pages govern the file, who owns the review boundary, and where a correction should start. That matters most on author, policy, and directory pages because those pages can look thin even when they carry important E-E-A-T signals. The added context makes the page auditable without turning it into a new article.
- PubMed for published biomedical literature and review context.
- ClinicalTrials.gov for registered trial status and study records.
- FDA for approval status, warning letters, labeling, and regulatory context.
Frequently Asked Questions
How should I verify this page?
Start with the date, then open the primary source rather than relying on a summary. For medical or regulatory context, check PubMed, ClinicalTrials.gov, and FDA records. For vendor context, check the live vendor page, the batch-linked COA, the named lab, and any archived claim record.
Does this page provide medical advice?
No. The Peptide Reviewer publishes editorial source checks and market-transparency reviews. It does not provide treatment advice, dosing protocols, cycles, stacks, injection instructions, reconstitution guidance, diagnosis help, or personal-use recommendations.
Can affiliate relationships change the conclusion?
No. Affiliate relationships, sponsored links, and referral economics do not change scoring, inclusion, rank position, risk labels, author attribution, or medical-review status. Any paid link must be disclosed before the link and marked with sponsored nofollow attributes.
What happens if a source changes?
The page should be updated through the corrections process. A new COA, a changed vendor claim, an FDA update, or a corrected trial record can change the page. Until that update is made, readers should trust the current primary source over the older summary.
Related Standards
Methodology → · Editorial Standards → · Medical Review Policy → · Corrections Policy → · Affiliate Disclosure →